Önsüz Ü., Can G.
SUPPORTIVE CARE IN CANCER, cilt.34, sa.3, ss.1-12, 2026 (SCI-Expanded, Scopus)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
34
Sayı:
3
-
Basım Tarihi:
2026
-
Doi Numarası:
10.1007/s00520-026-10512-5
-
Dergi Adı:
SUPPORTIVE CARE IN CANCER
-
Derginin Tarandığı İndeksler:
Scopus, Science Citation Index Expanded (SCI-EXPANDED), CINAHL, EMBASE, MEDLINE
-
Sayfa Sayıları:
ss.1-12
-
İstanbul Üniversitesi-Cerrahpaşa Adresli:
Evet
Özet
Abstract
Purpose
This study was conducted to evaluate the impact of the ONKOSIS mobile application, developed within the scope of the study, on the management of chemotherapy-related symptoms and quality of life.
Methods
This randomized controlled, single-blind experimental design study was carried out with the participation of 199 patients at the Kocaeli University Semahat Aracı Oncology and Palliative Care Center, Outpatient Chemotherapy Unit. In the study, which used simple randomization, the intervention group consisted of 98 patients and the control group consisted of 101 patients. During chemotherapy treatment, in addition to standard care for symptom management, the intervention group used the ONKOSIS mobile application, while the control group used a demo mobile application. The study data were obtained through the Diagnostic Form, Nightingale Symptom Assessment Scale, Coping with Chemotherapy Symptoms Form, and patient satisfaction survey. The follow-up frequency was planned according to the type of treatment protocol applied to the patients. Patients who received four cycles of treatment were followed up after the 2nd, 3rd, and 4th cycles, while patients who received six cycles of treatment were followed up after the 2nd, 4th, and 6th cycles.
Results
The study group had a mean age of 47.18 ± 13.83; 74.4% were female. Treatment cycles of 2, 3, or 4 weeks were provided for 26.6% of patients receiving treatment for gastrointestinal cancer, 21.6% for breast cancer, and 17.1% for lung cancer. Sociodemographic and clinical characteristics were similar between groups. Although the intervention group exhibited greater initial symptom burden (higher N-SAS scores at T1/T2), their symptom trajectory improved significantly over time compared to the control group, supporting the role of mHealth in enhancing outcomes. The use of ONKOSIS improved quality of life and patient satisfaction but did not reduce unscheduled healthcare visits.
Conclusion
The ONKOSIS mobile application was found to be an effective tool in supporting symptom management and improving the quality of life for cancer patients during the treatment process. It was determined that the widespread adoption of the mobile application in cancer care could contribute to improving patient outcomes and enhancing care quality.
Trial registration
ClinicalTrials.gov ID: NCT05946070. Registered on June 22, 2023